2F-QMPSB explained
2F-QMPSB (SGT-13) is an arylsulfonamide-based synthetic cannabinoid that is a fluorinated derivative of QMPSB and has been sold as a designer drug.[1] Its identification was first reported by a forensic laboratory in Italy in January 2019,[2] and it was made illegal in Latvia shortly afterwards.[3] [4] Fluorination of the tail group is a common strategy to increase potency at cannabinoid receptors which is seen in many related series of compounds.[5] [6]
See also
Notes and References
- Tsochatzis ED, Alberto Lopes J, Holland MV, Reniero F, Palmieri G, Guillou C . Identification and Analytical Characterization of a Novel Synthetic Cannabinoid-Type Substance in Herbal Material in Europe. . Molecules . 2021 . 26 . 4 . 793 . 10.3390/molecules26040793 . 33546439 . 7913736 . free .
- Web site: NPS2019 . Belgian Early Warning System on Drugs (BEWSD) .
- Web site: Centre for Disease Prevention and Control . Par aizlieguma noteikšanu vielai 2F-QMPSB un tās saturošiem izstrādājumiem . On the Prohibition of 2F-QMPSB and Articles Containing It . Latvian . Latvian Journal: Legal Acts of the Republic of Latvia . 17 January 2019 .
- Web site: Уважаемые эксперты . Dear experts . Russian . Aipsin Drugs .
- Banister SD, Stuart J, Kevin RC, Edington A, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Hibbs DE, Glass M, Connor M, McGregor IS, Kassiou M . 6 . Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135 . ACS Chemical Neuroscience . 6 . 8 . 1445–58 . August 2015 . 25921407 . 10.1021/acschemneuro.5b00107 .
- Yang SW, Smotryski J, Matasi J, Ho G, Tulshian D, Greenlee WJ, Brusa R, Beltramo M, Cox K . 6 . Structure-activity relationships of 2,4-diphenyl-1H-imidazole analogs as CB2 receptor agonists for the treatment of chronic pain . Bioorganic & Medicinal Chemistry Letters . 21 . 1 . 182–5 . January 2011 . 21115245 . 10.1016/j.bmcl.2010.11.044 .
